Mogamulizumab
Records for this ingredient, by country (identity only).
ATC L01FX09 · 10 markets · 12 records
AU 3 records · 2 shown of 2
- 20 mg/5 mLinjectionPOTELIGEO
- 20 mg per mL / per unit basis not statedinjectionPOTELIGEO mogamulizumab 4 mg/mL concentrate for solution for infusion vial
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
US 1 records · 1 shown of 1
- 4 mg per mL / per unit basis not statedinjectionPOTELIGEO
GB 1 records · 1 shown of 1
- 20 mg/5 mLinjectionPoteligeo 20mg/5ml concentrate for solution for infusion vials
CA 1 records · 1 shown of 1
- 4 mg per mL / per unit basis not statedliquidPOTELIGEO
SG 1 records · 1 shown of 1
- 20 mg/5 mLinjectionPOTELIGEO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/5ML
ES 1 records · 1 shown of 1
- 4 mg/1 mLinjectionPOTELIGEO
TW 1 records · 1 shown of 1
- 4 mg per mL / per unit basis not statedinjectionPOTELIGEO 4 mg/mL concentrate for solution forinfusion波替立久濃縮靜脈輸注液
JP 1 records · 1 shown of 1
- 20 mg/5 mLinjectionポテリジオ点滴静注20mg
EU 1 records · 0 shown of 0
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
FR 1 records · 1 shown of 1
- 4 mg/1 mLinjectionPOTELIGEO 4 mg/mL, solution à diluer pour perfusion
Some strengths are recorded without a per mL / per unit basis. They are shown as recorded and are not compared with other markets.
| Strength / form / release | US | GB | CA | AU | SG | ES | TW | JP | EU | FR |
|---|---|---|---|---|---|---|---|---|---|---|
| 20 mg/5 mL injection | Poteligeo 20mg/5ml concentrate for solution for infusion vials | POTELIGEO | POTELIGEO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/5ML | ポテリジオ点滴静注20mg | ||||||
| 4 mg per mL / per unit basis not stated cannot compare injection | POTELIGEO | POTELIGEO 4 mg/mL concentrate for solution forinfusion 波替立久濃縮靜脈輸注液 | ||||||||
| 4 mg/1 mL injection | POTELIGEO | POTELIGEO 4 mg/mL, solution à diluer pour perfusion | ||||||||
| 4 mg per mL / per unit basis not stated cannot compare liquid | POTELIGEO | |||||||||
| 20 mg per mL / per unit basis not stated cannot compare injection | POTELIGEO mogamulizumab 4 mg/mL concentrate for solution for infusion vial | |||||||||
unknown | POTELIGEO | POTELIGEO |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
2 more strength/form rows are recorded only in CA · ES · FR and are not shown in this table. Hay 2 filas de concentración/forma registradas solo en CA · ES · FR que no se muestran en esta tabla. 另有 2 个规格/剂型仅在 CA · ES · FR 有记录（未在本表显示）。 另有 2 個規格/劑型僅在 CA · ES · FR 有記錄（未在本表顯示）。
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.